187 related articles for article (PubMed ID: 33773987)
1. Long-Term Effects of Sirolimus on Human Skin TSC2-Null Fibroblast‒Like Cells.
Cai X; Fan Q; Kang GS; Grolig K; Shen X; Billings EM; Pacheco-Rodriguez G; Darling TN; Moss J
J Invest Dermatol; 2021 Sep; 141(9):2291-2299.e2. PubMed ID: 33773987
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
3. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
[TBL] [Abstract][Full Text] [Related]
4. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
6. Aberrant mTOR/autophagy/Nurr1 signaling is critical for TSC-associated tumor development.
Wang Y; Li C; Zhang Y; Zha X; Zhang H; Hu Z; Wu C
Biochem Cell Biol; 2021 Oct; 99(5):570-577. PubMed ID: 34463540
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
8. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
9. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
10. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
Alayev A; Sun Y; Snyder RB; Berger SM; Yu JJ; Holz MK
Cell Cycle; 2014; 13(3):371-82. PubMed ID: 24304514
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
14. Fibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: evidence for a novel therapeutic strategy?
Chan JY; Wang KH; Fang CL; Chen WY
PLoS One; 2014; 9(2):e89467. PubMed ID: 24558502
[TBL] [Abstract][Full Text] [Related]
15. Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
Filippakis H; Belaid A; Siroky B; Wu C; Alesi N; Hougard T; Nijmeh J; Lam HC; Henske EP
Sci Rep; 2018 Sep; 8(1):14161. PubMed ID: 30242175
[TBL] [Abstract][Full Text] [Related]
16. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
[TBL] [Abstract][Full Text] [Related]
17. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
[TBL] [Abstract][Full Text] [Related]
18.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
19. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.
Inoki K; Li Y; Xu T; Guan KL
Genes Dev; 2003 Aug; 17(15):1829-34. PubMed ID: 12869586
[TBL] [Abstract][Full Text] [Related]
20. Dynamic analysis of 4E-BP1 phosphorylation in neurons with Tsc2 or Depdc5 knockout.
Iffland PH; Barnes AE; Baybis M; Crino PB
Exp Neurol; 2020 Dec; 334():113432. PubMed ID: 32781001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
